---
figid: PMC10301446__pharmaceuticals-16-00802-g004
pmcid: PMC10301446
image_filename: pharmaceuticals-16-00802-g004.jpg
figure_link: /pmc/articles/PMC10301446/figure/pharmaceuticals-16-00802-f004/
number: Figure 4
figure_title: ''
caption: 'Metabolic pathway and related metabolic enzymes for the transformation of
  (A) DOX to (B) doxorubicinol and (C) doxorubicin semiquinone, major metabolites
  of DOX. CBR: carbonyl reductase; POR: cytochrome P450 oxidoreductase; SOD: superoxide
  dismutase. Arrows represent the metabolic conversion.'
article_title: Recent Advances in Doxorubicin Formulation to Enhance Pharmacokinetics
  and Tumor Targeting.
citation: Jihoon Lee, et al. Pharmaceuticals (Basel). 2023 Jun;16(6):802.
year: '2023'

doi: 10.3390/ph16060802
journal_title: Pharmaceuticals
journal_nlm_ta: Pharmaceuticals (Basel)
publisher_name: MDPI

keywords:
- doxorubicin (DOX)
- formulation strategy
- drug resistance
- oral formulation

---
